Skip to main content

Global Peptide Based Metabolic Disorders Therapeutics Market Anticipated To Register A CAGR Of 11.8% during 2017 to 2022

The purpose of this comprehensive forecast report presented by Fact.MR is to elaborate the various market projections impacting the global peptide based metabolic disorders therapeutics market during the period through 2017-2022. This assessment delivers high-end statistics concerning market size, growth in trends and revenue share (US& Mn) linked to different geographies and segmentation types. Readers can acquire precise insights about market growth trends along with upcoming opportunities that are expected to reshape the overall structure of the peptide based metabolic disorders therapeutics market during the forecast period.
Request for a Free Sample Report of Concerned Market - https://www.factmr.com/connectus/sample?flag=S&rep_id=187
With respect to the global peptide based metabolic disorders therapeutics market, according to the market observation in 2016 and 2017, the region of North America is expected to dominate the global market in terms of higher market share. In terms of revenues, North America is poised to grow at a higher growth rate, registering a CAGR of 10.6% throughout the period of forecast of 2017 to 2022. This region is expected to show the highest market attractiveness index, and is the most lucrative region for the growth of the global peptide based metabolic disorders therapeutics market. Middle East and Africa (MEA) and Latin America regions will show slower growth rate as compared to North America, as well as a comparatively low market revenue share
The Asia-Pacific excluding Japan (APEJ) region had shown rapid growth in the past with respect to global peptide based metabolic disorders therapeutics market, and is poised to reflect a higher growth rate, as fast as North America. APEJ will register a CAGR of 10.5% during the forecast period. The main reasons for this kind of growth is the strict government regulations for the upcoming players, higher number of pharmaceutical companies, increased foreign direct investment and development of technologies. Moreover, the government encourages to increase the investment in the healthcare industry to discover and invent new methods & technologies to better the health of the patients and enhance treatment outcomes. Europe region, following APEJ region, also reflects itself as a positive platform for the growth of the global peptide based metabolic disorders therapeutics market.
The liraglutide segment by drug class reflects a higher market share by revenue and dominates the global market by drug class. The market share of this segment is more than two and a half times than that of the exenatide segment as of 2017. However, it is anticipated that this segment will lose BPS by the end of 2022. The growth of liraglutide segment is slow as compared to the growth rates of the exenatide and others segments throughout the period of forecast.
The hospital pharmacies segment by distribution channel reflect a higher market share by revenue and a higher growth rate throughout the period of forecast. However, the online pharmacies segment shows even higher growth rate as compared to hospital pharmacies segment, and is expected to register a CAGR of 11.8% during the period of forecast. But the market share of this segment is less; hospital pharmacies segment enjoys a market share more than three times than that of online pharmacies segment. The online pharmacies segment is expected to enjoy a gain in the BPS by the end of 2022. On the other hand, the retail pharmacies segment shows moderate growth rate, yet higher than that of the hospital pharmacies segment and a market share more than double than that of the online pharmacies segment as of 2017.
Have Any Question? Ask Our Industry Experts – https://www.factmr.com/connectus/sample?flag=AE&rep_id=187
Competition Tracking
The report also profiles companies that are expected to remain active in the expansion of the global peptide based metabolic disorders therapeutics market through 2022, which include AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Novo Nordisk A/S, Merck & Co., Inc., Ipsen S.A, Eli Lilly and Company, CordenPharma International, and Bachem Holding AG.
Labels:

Comments

Post a Comment

Popular posts from this blog

Electrosurgery Devices Market: Radiofrequency Electrosurgery Devices will Remain the Top-Selling Product

On the back of rising ageing population, increased instances of surgical procedures and technological innovations, the market for electrosurgical devices is likely to slate lucrative growth triggers in the coming years. Significant spike in surgical procedures pertaining neurology, cardiology, gynecology, and several other general surgeries, electrosurgery devices market is in the cusp of exponential growth. Owing to technological innovations the electrosurgery market in North America has demonstrated growth traction over the years. However, increased healthcare spending towards minimally invasive treatment in Asia-Pacific region is expected to propel the market forward, thus contributing as one of the fastest regional hub in electrosurgery devices market. However, factors such as significant product recalls owing to incompliance with FDA framework remain potential challenges for the growth trajectory. Get sample of this report at https://www.factmr.com/connectus/sample?flag=S...
Post a Comment
Read more

North America to Maintain its Leader Status for the Dermatology Devices Market

 Increasing geriatric population across the world have propelled the demand for the dermatology devices, which in turn has contributed to the growth of the dermatology devices market. Rising adoption of dermatology devices in parallel to the rapid adoption of technology in the dermatology clinics and hospitals for treating skin disorders have been prominent factors for the growth of dermatology devices market. Spur in the spending capability of consumers have facilitated the access to these devices. Pervasiveness of skin disorders has been rising at the global level, which has created demand for acute treatment devices. Developments in the treatment methodologies such as liposuction devices and laser instruments have been successful in attracting the attention of the consumers. A recent report published by Fact.MR states that the global dermatology devices market is anticipated to surpass the whopping value of US$ 1,000 Mn by 2022. Browse Full Report with TOC 'https://www.factm...
Post a Comment
Read more

Lithotripsy Devices Market: Non-Invasive ESWL Witnessing Immense Traction

The report offers a crisp overview of the lithotripsy devices market, which includes an introduction to the lithotripsy devices market in tandem with a definition of the target product – lithotripsy devices. A systematic breakdown of the lithotripsy devices market has been offered in this chapter, which implies scope of the research involved. Size of lithotripsy devices market has been studied in terms of volume (tons) and value (MN), and forecast on the lithotripsy devices market has been offered for the period between 2018 and 2026. The lithotripsy devices market is projected to continue its steady growth due to the burgeoning cases of kidney stones, coupled with the surging demand for minimally invasive medical treatments. According to Fact.MR report, the  lithotripsy devices market  is anticipated to accelerate at 4.3% CAGR during 2018-2026 to reach a value of US$ 1,095.2 MN by the end of 2026. In recent past, lithotripsy has become the most pref...
Post a Comment
Read more